1.Clinicopathological characteristics and prognosis of patients with adenosquamous lung carcinoma.
Ye GUO ; Lin JIA ; Guo-Guang SHAO ; Hong-Wei SUN ; Xing-Xing WANG ; Guan-Jun WANG ; Ke-Wei MA
Journal of Huazhong University of Science and Technology (Medical Sciences) 2015;35(3):350-355
This study was aimed to characterize clinicopathological features and prognosis of patients with adenosquamous lung carcinoma (ASC). Among the 2531 patients with lung cancer who underwent surgery between January 2000 and June 2012 in our hospital, 59 were histologically diagnosed as having ASC. The clinicopathological features and follow-up data of ASC patients were collected and analyzed statistically. Superior lobectomy was accomplished in 40 patients, middle and inferior lobectomy in 3, lobectomy plus partial resection of contralateral lung in 5, partial lung resection in 4, and pneumonectomy in 7. Moreover, 22 cases were found to be adenocarcinoma-predominant, and 18 to be squamous cell carcinoma-predominant. The median survival time was 13.6 months, and the 1-, 3-, and 5-year survival rates were 59.9%, 36.4% and 31.2%, respectively. Of the 52 cases with tissue specimens available, 11 had an EGFR mutation (21.2%) and 2 had a KRAS mutation (3.8%). Multivariate analysis showed that histology subtype, pleural invasion, TNM stage, and postoperative treatment were all independent prognostic factors. The data from the current study demonstrated that SCC-predominant histology represents a better prognosis of ASC. Histology subtype, pleural invasion, TNM stage, and postoperative treatment are independent prognostic factors for ASC and adjuvant therapy may help control the disease.
Adult
;
Aged
;
Carcinoma, Adenosquamous
;
genetics
;
pathology
;
surgery
;
Diagnosis, Differential
;
Female
;
Humans
;
Lung Neoplasms
;
genetics
;
pathology
;
surgery
;
Male
;
Middle Aged
;
Mutation
;
Prognosis
;
Proto-Oncogene Proteins p21(ras)
;
genetics
;
Receptor, Epidermal Growth Factor
;
genetics
;
Retrospective Studies
;
Survival Analysis
2.Clinical Features Reflect Exon Sites of EGFR Mutations in Patients with Resected Non-Small-Cell Lung Cancer.
Im Il NA ; Jin Kyung RHO ; Yun Jung CHOI ; Cheol Hyeon KIM ; Jae Soo KOH ; Baek Yeol RYOO ; Sung Hyun YANG ; Jae Cheol LEE
Journal of Korean Medical Science 2007;22(3):393-399
The aim of the current study was to determine the clinical significance according to the subtypes of epidermal growth factor receptor (EGFR) mutations and presence of KRAS mutations in operable non-small-cell lung cancer (NSCLC). We sequenced exons 18-21 of the EGFR tyrosine kinase domain and examined mutations in codons 12 and 13 of KRAS in tissues of patients with NSCLC who had undergone surgical resection. EGFR mutations were more frequent in never-smokers than smokers (33% vs. 14%, respectively; p=0.009) and in females than in males (31% vs. 16%, respectively; p=0.036). Mutations in exon 18-19 and 20-21 were found in 10 and 22 patients, respectively. Never-smokers and broncho-alveolar cell carcinoma features were positively associated with a mutation in exon 18-19 (p=0.027 and 0.016, respectively). The five-year survival rate in patients with a mutation in exons 18-19 (100%) was higher than that in patients without such mutation (47%; p=0.021). KRAS mutations were found in 16 patients (12%) and were not related to the overall survival (p=0.742). Patients with an EGFR mutation in exons 18-19 had better survival than patients without such mutation. Subtypes of EGFR mutations may be prognostic factors in patients undergoing curative resection.
Adult
;
Aged
;
Aged, 80 and over
;
Carcinoma, Non-Small-Cell Lung/diagnosis/*genetics/*surgery
;
Disease-Free Survival
;
*Exons
;
Female
;
Humans
;
Lung Neoplasms/diagnosis/*genetics/*surgery
;
Male
;
Middle Aged
;
*Mutation
;
Proto-Oncogene Proteins p21(ras)/genetics
;
Receptor, Epidermal Growth Factor/*genetics
;
Sex Factors
;
Treatment Outcome
3.Advance in pulmonary adenocarcinoma with micropapillary pattern.
Jing ZHANG ; Zhi-yong LIANG ; Tong-hua LIU
Chinese Journal of Pathology 2011;40(3):202-205
Adenocarcinoma
;
drug therapy
;
genetics
;
metabolism
;
pathology
;
surgery
;
Adenocarcinoma, Bronchiolo-Alveolar
;
drug therapy
;
genetics
;
metabolism
;
pathology
;
surgery
;
Adenocarcinoma, Papillary
;
metabolism
;
pathology
;
Cadherins
;
metabolism
;
Diagnosis, Differential
;
Genes, erbB-1
;
genetics
;
Humans
;
Lung Neoplasms
;
drug therapy
;
genetics
;
metabolism
;
pathology
;
surgery
;
Lymphatic Metastasis
;
Mucin-1
;
metabolism
;
Mutation
;
Neoplasm Invasiveness
;
beta Catenin
;
metabolism